Loading clinical trials...

RECRUITING

Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure.

NCT03825458•Hospices Civils de Lyon

Summary

The " CirB-RNA " cohort aims to create a biological collection associated with clinical and biological data from patients with hepatitis B infection. This project is part of a much larger program that aims to characterize and quantify circulating viral RNAs as a possible new biomarker of hepatitis B functional cure.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adults patients and minor children over 6 years of age (in Lyon) with acute or chronic hepatitis B or presenting with HBsAg loss (with/without HBs seroconversion). (Co-infected patients with HDV and/or HCV and/or HIV are eligible)
•Patients requiring blood sampling for medical care at the time of the medical appointment.
•Informed patients who do not refuse to participate.
•Persons not affiliated to a social security scheme and persons receiving medical assistance from the state may be asked to participate in the study

Exclusion Criteria

•Patients participating at the time of the inclusion to an interventional trial evaluating a drug likely to interfere with this study.
•Persons deprived of their liberty by a judicial or administrative decision
•Adults who are subject to a legal protection measure
•Children less than 6 years old (in Lyon)

Locations (6)

Hepatology department - Groupement Hospitalier Nord - Hôpital de la Croix-Rousse

Lyon, France

Hôpital de la Croix-Rousse - Service de maladies infectieuses et tropicales

Lyon, France

Department of Hepato-gastroenterology and pediatric nutrition - Hôpital Femme-Mère Enfant

Lyon, France

Gastroenterology and Hepatology department - • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy

Gastroenterology and Hepatology department - • Università degli Studi di Palermo

Palermo, Italy

Infectious diseases and hepatology unit - Azienda Ospedaliero

Parma, Italy

Key Dates

Start Date

February 25, 2019

Primary Completion Date

June 25, 2029

Completion Date

June 25, 2029

Last Updated

November 18, 2023

Enrollment

3,500

ESTIMATED participants

Conditions

Hepatitis B

Interventions

Blood sampling

OTHER

Contacts

Fabien ZOULIM, Pr

CONTACT

04 26 10 93 55 fabien.zoulim@chu-lyon.fr

Massimo LEVERO, Pr

CONTACT

04 72 68 19 79 massimo.levrero@inserm.fr

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

NCT07024641

Hepatitis B Virus Infection

View study

RECRUITINGPHASE1

Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B

NCT06671093

Chronic Hep BChronic Hepatitis b+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure.

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B

Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure

hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis

HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series